CStone’s Anti-CTLA-4 Antibody CS1002 Receives IND Approval in China
- Monday, August 27, 2018, 21:16
- Business
- Add a comment
SUZHOU, China, Aug. 27, 2018 /PRNewswire/ — CStone Pharmaceuticals (CStone) announced today that its IND application for CS1002, an investigational cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) monoclonal antibody, has been approved by the China National Drug Administration (CNDA)….
Source: https://www.prnewswire.com:443/news-releases/cstones-anti-ctla-4-antibody-cs1002-receives-ind-approval-in-china-300703022.html
About the Author
adminasapcorp has written 38957 stories on this site.